The US government has agreed to pay Pfizer and BioNTech $1.95 billion to secure access to 100 million doses of their coronavirus vaccine on approval, just days after promising
Concerns have emerged about access to some potential COVID-19 vaccines after pharma executives from three companies said they expect to make profits from their products in evidence to a US
The UK has secured 90 million doses of two different COVID-19 vaccines from BioNTech/Pfizer and Valneva, with an option of 40 million doses if they check out in trials.
The FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 class to gain a foothold in this indication.
Two of Pfizer and BioNTech’s potential COVID-19 vaccines have been granted Fast Track status by the FDA, a process designed to hasten their development and review.
More than 20 pharma companies including GlaxoSmithKline, Novartis and Pfizer have joined forces to create a $1 billion fund to save the pipeline of antibiotics drugs, after several biotechs